Are Investors Overreacting to Pfizer ' s Underwhelming Forecast for 2024?

Pfizer (NYSE: PFE) stock has been in the dumps this year. It is struggling due to declining demand for its COVID products. And it may take some years before its top line starts rising meaningfully again. The company's recent forecast didn't help matters, either. But with the stock losing close to…#pfe #pfizer #seagen #davidjagielski #motleyfool

Source: Reuters: Health - December 23, 2023 Category: Consumer Health News Source Type: news